In contrast, sorafenib which targets c-kit and PDGFRβ as well as RAF, VEGFR2, was poorly tolerated and did not show any tumour response in a phase 1 trial on children with NF1 and plexiform neurofibromas [169]. This evidence concerns the gene NF1 and neoplasm.